M D Hellmann1, T-W Kim2, C B Lee3, B-C Goh4, W H Miller5, D-Y Oh6, R Jamal7, C-E Chee4, L Q M Chow8, J F Gainor9, J Desai10, B J Solomon11, M Das Thakur12, B Pitcher13, P Foster14, G Hernandez12, M J Wongchenko12, E Cha14, Y-J Bang6, L L Siu15, J Bendell16. 1. Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, USA. Electronic address: hellmanm@mskcc.org. 2. Department of Oncology, Asan Medical Center, University of Ulsan, Seoul, South Korea. 3. UNC Lineberger Comprehensive Cancer Center, Division of Hematology and Oncology, University of North Carolina at Chapel Hill, USA. 4. Department of Haematology-Oncology, National University Cancer Institute, Singapore, National University Hospital, Singapore. 5. Segal Cancer Center, Jewish General Hospital, Department of Medicine, Division of Experimental Medicine, McGill University, Montreal, Canada. 6. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea. 7. Department of Hematology-Oncology, Centre Hospitalier de l'Université de Montréal (CHUM), University of Montreal, Montréal, Canada. 8. Division of Medical Oncology, Department of Medicine, University of Washington, Seattle. 9. Massachusetts General Hospital Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston, USA. 10. Department of Medical Oncology, Royal Melbourne Hospital, University of Melbourne, Melbourne. 11. Department of Medical Oncology, Peter MacCallum Cancer Center, Melbourne, Australia. 12. Oncology Biomarker Development, Genentech, Inc., South San Francisco, USA. 13. Biostatistics, Hoffmann-La Roche Ltd, Mississuaga, Canada. 14. Product Development Oncology, Genentech, Inc., South San Francisco, USA. 15. Department of Medicine, Princess Margaret Cancer Centre-University Health Network, University of Toronto, Toronto, Canada. 16. Drug Development Unit Nashville, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, USA.
Abstract
BACKGROUND: Preclinical evidence suggests that MEK inhibition promotes accumulation and survival of intratumoral tumor-specific T cells and can synergize with immune checkpoint inhibition. We investigated the safety and clinical activity of combining a MEK inhibitor, cobimetinib, and a programmed cell death 1 ligand 1 (PD-L1) inhibitor, atezolizumab, in patients with solid tumors. PATIENTS AND METHODS: This phase I/Ib study treated PD-L1/PD-1-naive patients with solid tumors in a dose-escalation stage and then in multiple, indication-specific dose-expansion cohorts. In most patients, cobimetinib was dosed once daily orally for 21 days on, 7 days off. Atezolizumab was dosed at 800 mg intravenously every 2 weeks. The primary objectives were safety and tolerability. Secondary end points included objective response rate, progression-free survival, and overall survival. RESULTS: Between 27 December 2013 and 9 May 2016, 152 patients were enrolled. As of 4 September 2017, 150 patients received ≥1 dose of atezolizumab, including 14 in the dose-escalation cohorts and 136 in the dose-expansion cohorts. Patients had metastatic colorectal cancer (mCRC; n = 84), melanoma (n = 22), non-small-cell lung cancer (NSCLC; n = 28), and other solid tumors (n = 16). The most common all-grade treatment-related adverse events (AEs) were diarrhea (67%), rash (48%), and fatigue (40%), similar to those with single-agent cobimetinib and atezolizumab. One (<1%) treatment-related grade 5 AE occurred (sepsis). Forty-five (30%) and 23 patients (15%) had AEs that led to discontinuation of cobimetinib and atezolizumab, respectively. Confirmed responses were observed in 7 of 84 patients (8%) with mCRC (6 responders were microsatellite low/stable, 1 was microsatellite instable), 9 of 22 patients (41%) with melanoma, and 5 of 28 patients (18%) with NSCLC. Clinical activity was independent of KRAS/BRAF status across diseases. CONCLUSIONS: Atezolizumab plus cobimetinib had manageable safety and clinical activity irrespective of KRAS/BRAF status. Although potential synergistic activity was seen in mCRC, this was not confirmed in a subsequent phase III study. CLINICALTRIALS.GOV IDENTIFIER: NCT01988896 (the investigators in the NCT01988896 study are listed in the supplementary Appendix, available at Annals of Oncology online).
BACKGROUND: Preclinical evidence suggests that MEK inhibition promotes accumulation and survival of intratumoral tumor-specific T cells and can synergize with immune checkpoint inhibition. We investigated the safety and clinical activity of combining a MEK inhibitor, cobimetinib, and a programmed cell death 1 ligand 1 (PD-L1) inhibitor, atezolizumab, in patients with solid tumors. PATIENTS AND METHODS: This phase I/Ib study treated PD-L1/PD-1-naive patients with solid tumors in a dose-escalation stage and then in multiple, indication-specific dose-expansion cohorts. In most patients, cobimetinib was dosed once daily orally for 21 days on, 7 days off. Atezolizumab was dosed at 800 mg intravenously every 2 weeks. The primary objectives were safety and tolerability. Secondary end points included objective response rate, progression-free survival, and overall survival. RESULTS: Between 27 December 2013 and 9 May 2016, 152 patients were enrolled. As of 4 September 2017, 150 patients received ≥1 dose of atezolizumab, including 14 in the dose-escalation cohorts and 136 in the dose-expansion cohorts. Patients had metastatic colorectal cancer (mCRC; n = 84), melanoma (n = 22), non-small-cell lung cancer (NSCLC; n = 28), and other solid tumors (n = 16). The most common all-grade treatment-related adverse events (AEs) were diarrhea (67%), rash (48%), and fatigue (40%), similar to those with single-agent cobimetinib and atezolizumab. One (<1%) treatment-related grade 5 AE occurred (sepsis). Forty-five (30%) and 23 patients (15%) had AEs that led to discontinuation of cobimetinib and atezolizumab, respectively. Confirmed responses were observed in 7 of 84 patients (8%) with mCRC (6 responders were microsatellite low/stable, 1 was microsatellite instable), 9 of 22 patients (41%) with melanoma, and 5 of 28 patients (18%) with NSCLC. Clinical activity was independent of KRAS/BRAF status across diseases. CONCLUSIONS:Atezolizumab pluscobimetinib had manageable safety and clinical activity irrespective of KRAS/BRAF status. Although potential synergistic activity was seen in mCRC, this was not confirmed in a subsequent phase III study. CLINICALTRIALS.GOV IDENTIFIER: NCT01988896 (the investigators in the NCT01988896 study are listed in the supplementary Appendix, available at Annals of Oncology online).
Authors: Li Liu; Patrick A Mayes; Stephen Eastman; Hong Shi; Sapna Yadavilli; Tianqian Zhang; Jingsong Yang; Laura Seestaller-Wehr; Shu-Yun Zhang; Chris Hopson; Lyuben Tsvetkov; Junping Jing; Shu Zhang; James Smothers; Axel Hoos Journal: Clin Cancer Res Date: 2015-01-14 Impact factor: 12.531
Authors: Achim Rittmeyer; Fabrice Barlesi; Daniel Waterkamp; Keunchil Park; Fortunato Ciardiello; Joachim von Pawel; Shirish M Gadgeel; Toyoaki Hida; Dariusz M Kowalski; Manuel Cobo Dols; Diego L Cortinovis; Joseph Leach; Jonathan Polikoff; Carlos Barrios; Fairooz Kabbinavar; Osvaldo Arén Frontera; Filippo De Marinis; Hande Turna; Jong-Seok Lee; Marcus Ballinger; Marcin Kowanetz; Pei He; Daniel S Chen; Alan Sandler; David R Gandara Journal: Lancet Date: 2016-12-13 Impact factor: 79.321
Authors: Dung T Le; Jennifer N Uram; Hao Wang; Bjarne R Bartlett; Holly Kemberling; Aleksandra D Eyring; Andrew D Skora; Brandon S Luber; Nilofer S Azad; Dan Laheru; Barbara Biedrzycki; Ross C Donehower; Atif Zaheer; George A Fisher; Todd S Crocenzi; James J Lee; Steven M Duffy; Richard M Goldberg; Albert de la Chapelle; Minori Koshiji; Feriyl Bhaijee; Thomas Huebner; Ralph H Hruban; Laura D Wood; Nathan Cuka; Drew M Pardoll; Nickolas Papadopoulos; Kenneth W Kinzler; Shibin Zhou; Toby C Cornish; Janis M Taube; Robert A Anders; James R Eshleman; Bert Vogelstein; Luis A Diaz Journal: N Engl J Med Date: 2015-05-30 Impact factor: 91.245
Authors: Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi Journal: Nature Date: 2014-11-27 Impact factor: 49.962
Authors: Jonathan E Rosenberg; Jean Hoffman-Censits; Tom Powles; Michiel S van der Heijden; Arjun V Balar; Andrea Necchi; Nancy Dawson; Peter H O'Donnell; Ani Balmanoukian; Yohann Loriot; Sandy Srinivas; Margitta M Retz; Petros Grivas; Richard W Joseph; Matthew D Galsky; Mark T Fleming; Daniel P Petrylak; Jose Luis Perez-Gracia; Howard A Burris; Daniel Castellano; Christina Canil; Joaquim Bellmunt; Dean Bajorin; Dorothee Nickles; Richard Bourgon; Garrett M Frampton; Na Cui; Sanjeev Mariathasan; Oyewale Abidoye; Gregg D Fine; Robert Dreicer Journal: Lancet Date: 2016-03-04 Impact factor: 79.321
Authors: Louis Fehrenbacher; Joachim von Pawel; Keunchil Park; Achim Rittmeyer; David R Gandara; Santiago Ponce Aix; Ji-Youn Han; Shirish M Gadgeel; Toyoaki Hida; Diego L Cortinovis; Manuel Cobo; Dariusz M Kowalski; Filippo De Marinis; Mayank Gandhi; Bradford Danner; Christina Matheny; Marcin Kowanetz; Pei He; Federico Felizzi; Hina Patel; Alan Sandler; Marcus Ballinger; Fabrice Barlesi Journal: J Thorac Oncol Date: 2018-05-17 Impact factor: 15.609
Authors: Lee S Rosen; Patricia LoRusso; Wen Wee Ma; Jonathan W Goldman; Amy Weise; A Dimitrios Colevas; Alex Adjei; Salim Yazji; Angela Shen; Stuart Johnston; Hsin-Ju Hsieh; Iris T Chan; Branimir I Sikic Journal: Invest New Drugs Date: 2016-07-16 Impact factor: 3.850
Authors: Arjun V Balar; Matthew D Galsky; Jonathan E Rosenberg; Thomas Powles; Daniel P Petrylak; Joaquim Bellmunt; Yohann Loriot; Andrea Necchi; Jean Hoffman-Censits; Jose Luis Perez-Gracia; Nancy A Dawson; Michiel S van der Heijden; Robert Dreicer; Sandy Srinivas; Margitta M Retz; Richard W Joseph; Alexandra Drakaki; Ulka N Vaishampayan; Srikala S Sridhar; David I Quinn; Ignacio Durán; David R Shaffer; Bernhard J Eigl; Petros D Grivas; Evan Y Yu; Shi Li; Edward E Kadel; Zachary Boyd; Richard Bourgon; Priti S Hegde; Sanjeev Mariathasan; AnnChristine Thåström; Oyewale O Abidoye; Gregg D Fine; Dean F Bajorin Journal: Lancet Date: 2016-12-08 Impact factor: 79.321
Authors: Xiaoshan Zhang; Ran Zhang; Huiqin Chen; Li Wang; Chenghui Ren; Apar Pataer; Shuhong Wu; Qing H Meng; Min Jin Ha; Jeffrey Morris; Yuanxin Xi; Jing Wang; Jianhua Zhang; Don L Gibbons; John V Heymach; Funda Meric-Bernstam; John Minna; Stephen G Swisher; Jack A Roth; Bingliang Fang Journal: Am J Cancer Res Date: 2020-12-01 Impact factor: 6.166
Authors: Lauren Dennison; Amanda Ruggieri; Aditya Mohan; James Leatherman; Kayla Cruz; Skylar Woolman; Nilofer Azad; Gregory B Lesinski; Elizabeth M Jaffee; Mark Yarchoan Journal: Cancer Immunol Res Date: 2021-08-13 Impact factor: 11.151
Authors: David H Peng; B Leticia Rodriguez; Lixia Diao; Pierre-Olivier Gaudreau; Aparna Padhye; Jessica M Konen; Joshua K Ochieng; Caleb A Class; Jared J Fradette; Laura Gibson; Limo Chen; Jing Wang; Lauren A Byers; Don L Gibbons Journal: Nat Commun Date: 2021-05-10 Impact factor: 14.919
Authors: Brittany B Campbell; Melissa A Galati; Simone C Stone; Alexandra N Riemenschneider; Melissa Edwards; Sumedha Sudhaman; Robert Siddaway; Martin Komosa; Nuno M Nunes; Liana Nobre; A Sorana Morrissy; Matthew Zatzman; Michal Zapotocky; Lazar Joksimovic; Sangeetha N Kalimuthu; David Samuel; Gary Mason; Eric Bouffet; Daniel A Morgenstern; Melyssa Aronson; Carol Durno; David Malkin; John M Maris; Michael D Taylor; Adam Shlien; Trevor J Pugh; Pamela S Ohashi; Cynthia E Hawkins; Uri Tabori Journal: Cancer Discov Date: 2021-02-09 Impact factor: 39.397